This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Lupin updates on shipment of Mirabegron ER Tablets
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company is committed to address this observation comprehensively within stipulated time
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
